Disease-Targeted Therapies and eGFR Slope over 2 Years in IgA Nephropathy: A Systematic Review and Network Meta-Analysis
Background: Several disease-targeted therapies for IgA nephropathy have reported effects on eGFR slope over 2 years or longer in phase 3 trials, but they h